This morning, Zimmer Biomet announced its intention to spin-off its spine and dental businesses into a new public company. The new company would have revenues of approximately $890 million of which spine would account for 60%. The transaction is expected to be completed roughly 16 months from now, mid-2022.
Zimmer to Spin-off Spine and Dental Businesses
1 min read Premium comments
#spine#zimmerbiometSecondary
Wall Street initially is taking the announcement well. Larry Biegelsen at Wells Fargo noted in his morning comment to investors that the news did not come as a surprise to him since the company had been de-emphasizing the two businesses in recent commentary.
Last year, which was extremely difficult for all implant suppliers, sales of spine and dental had declined about 12%.
There will be much more information over the next few weeks so stay tuned.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.